vor 2 Jahren

Life Sciences Report 2017 / 2018

  • Text
  • Technology
  • Medicine
  • Pharma
  • Berlin
  • Innovative
  • Clinical
  • Sciences
  • Solutions
  • Pharmaceutical
  • Biotech
  • Diagnostics

26 Life

26 Life Sciences Report – Regenerative Medicine Regenerative Medicine Regenerative medicine encompasses a broad array of therapies. The focal areas for research and development in the German capital region Berlin-Brandenburg are tissue engineering, cell and gene therapies, stimulating the body’s own regeneration, and interactions between biomaterials and cells. Over the past few years, Berlin-Brandenburg has developed into one of the most important international centers for regenerative medicine. Around 30 companies and several research institutes inside and outside of universities are working in this dynamic and growing field in the region, focusing on the interface between biotechnology and medical technology. This work results in new approaches and products that receive international acclaim and have successfully established on the market. The clinical and economic importance of regenerative medicine As life expectancies increase, age-related illnesses are requiring more and more treatment. There is currently no cure for most of these illnesses. Regenerative medicine is focused on the hope of permanently curing these kinds of disorders. They harbor enormous market potential around the world. However, the commercialization of regenerative medicine has only just begun. Focus areas of the region include: • Musculoskeletal system transplants • Miniaturized organ cultures • Cardiac support systems and biohybrid cardiac valves • Immune cell therapies Small and mid-sized companies The region is distinguished by high-performing small and mid-sized companies working in the regenerative medicine field. CO.DON is one of the world’s leading specialists in cell therapies used to treat cartilage injuries, which it develops, produces, and markets in Germany. The company saw double-digit growth in 2016 in comparison to the previous year, and gained a new strategic investor in Bauerfeind AG. After a successful capital increase campaign involving almost 5 million euros at the start of 2017, the company received EU-wide approval in July of 2017 for Spherox, an autologous human medicine to treat cartilage defects in the knee. This gives CO.DON AG the opportunity to take over a market worth millions of euros with one of the very few human medicines regulated across the EU which has currently no European competitors in this market segment. TissUse GmbH has developed a unique “Multi-Organ- Chip” (MOC) platform that, for the first time ever, provides preclinical insight on the systemic level using human tissue. The chip consists of a miniaturized construct that simulates the activity of up to four human organs on a microscope slide. The next generation of MOC design at TissUse, a Human-on-a-Chip, will increase the number of intercon- © CO.DON Dirk Hessel CEO, CO.DON AG “Due to the large number of universities in Berlin and Brandenburg, we are able to find qualified employees and competent and committed partners for our research projects and our production plant in Teltow. The State of Brandenburg has supported us with various financing options, which we have combined with a partial financing of our clinical studies for the EU-wide approval of our joint cartilage preparations. This has given us the opportunity to modernize our research laboratories in order to keep pace with current international laboratory standards. In July 2017, we received EU-wide approval for our product and are pleased to be able to produce our highly innovative products for the EU market.”

Life Sciences Report – Regenerative Medicine 27 © TissUse Furthermore, there are many KMUs providing supporting expertise in areas like analysis, cell and bioreactor technologies and 3D bioprinting for regenerative medicine. Examples include Cellbricks (3D bioprinting) and Zellwerk GmbH. Zellwerk produces the rotating-disk Z® RP bioreactor and other bioreactors which can be used for GMP-compliant expansion of stem cells and immune cells used for cell therapy and to manufacture cell-seeded implants. Zellwerk and their bioreactors are part of the Horizon2020 project consortium AUTOSTEM, which is developing a closed, automated large scale production line for stem cells. TissUse 4-Organ-Chip nected organs. In the future, this chip could be used for disease modelling, an approach that could revolutionize drug development. In mid-2017 TissUse and ProBioGen signed a licensing and cooperation agreement to integrate ProBioGen’s Human Artificial Lymph Node Model into TissUse MOC technology to monitor effects of substances on the human immune system. TransTissue Technologie GmbH, founded by the Charité-Universitätsmedizin Berlin and a 100% subsidiary of BioTissue Technologies GmbH, has already developed two ATMPs (bone and cartilage transplant) and one medical product (cartilage repair) to a marketable state. The company develops cell-based tissue replacements and is working on 3D cultivation of cells from human bone and cartilage tissues. AutoTissue GmbH produces cardiovascular implants from animal tissues based on its patent-protected decellularization and sterilization technology. It has been involved in an international cooperation focused on the decellularization of homografts since 2016. In addition, the company offers processing and decellularization of xenogeneic tissues as a service. Basic research The German capital region stands out for its international research-based and clinical expertise. All of the basic areas of expertise and clinical disciplines needed to develop regenerative therapies are available. The internationally renowned Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) engages in basic research and initial early product developments in gene and cell therapy. The MDC spin-off project Captain T-Cell develops T-cell therapies to fight cancer. In 2016 it took first place in OneStart, the world’s largest start-up competition in health and life sciences. In addition to basic research at the Max Planck Institute for Molecular Genetics in Berlin, at the Brandenburg University of Technology Cottbus-Senftenberg and the Technische Universität Berlin, the capital region also offers outstanding biomaterials research and development, for instance at the Fraunhofer Institute for Applied Polymer Research in Potsdam-Golm and the Helmholtz Zentrum Geesthacht in Teltow. Applied research and translation The Berlin-Brandenburg Center for Regenerative Therapies (BCRT) is an outstanding successful international translation model in the area of applied research and in translating basic research into clinical applications. The institute researches the body’s own healing processes and develops new therapies and diagnostic tools based on © Charité - Kerstin Müller “The BCRT is an interdisciplinary research center with the goal of enhancing endogenous regeneration by cells, biomaterials and factors which are used to develop and implement innovative therapies and products. We have set new standards with translational structures and scientific successes, at both a regional and an international level. The German capital region provides perfect conditions for networking with important actors along the supply chain and translating innovations from basic research into clinics and industry.” Prof. Dr. Hans-Dieter Volk Director and Spokesman, Berlin-Brandenburg Center for Regenerative Therapies (BCRT)

Publications in English

Publikationen auf deutsch

Clusterreport Verkehr, Mobilität und Logistik
Automotive in der Hauptstadtregion Berlin-Brandenburg
Aerospace Industrie
Biotech- und Pharmaindustrie
Forschung für die Gesundheit
Gesundheitsversorgung und Prävention
Potenzialstudie Medizintourismus Berlin-Brandenburg_2015
Clusterbroschuere Gesundheitswirtschaft
Prävention und Gesundheitsförderung
Rehabilitation in Berlin und Brandenburg
Games Industrie in der Hauptstadtregion Berlin-Brandenburg
Digitale Wirtschaft in Berlin
Fernsehen in der Hauptstadtregion Berlin-Brandenburg
Fashion in Berlin
Best Practice Wireless in der Hauptstadtregion Berlin-Brandenburg
Medien und Kreativwirtschaft in Berlin-Brandenburg
Turbomaschinen und Kraftwerkstechnik
Energienetze und -speicher in der Hauptstadtregion Berlin-Brandenburg
Kreislaufwirtschaft in Berlin
Wasserwirtschaft in Berlin
Energietechnik in der Hauptstadtregion Berlin-Brandenburg
Inkubationsprogramme in der Energiewirtschaft
Service Packages für Unternehmen in Berlin
Unternehmensservice in den Berliner Bezirken
Berlin Partner: Unser Service fuer Sie